Literature DB >> 28233462

First-trimester prediction of surgical outcome in abnormally invasive placenta using the cross-over sign.

G Calì1, F Forlani1, G Minneci1, F Foti1, S Di Liberto1, A Familiari2, G Scambia2,3, F D'Antonio4.   

Abstract

OBJECTIVE: Ultrasound assessment of the relationship between the ectopic gestational sac and the endometrial line (cross-over sign; COS) in Cesarean scar pregnancy (CSP) has been shown to be useful in predicting the evolution of CSP towards different types of abnormally invasive placenta (AIP). The aim of this study was to ascertain whether the COS can be used to predict surgical outcome in women with AIP.
METHODS: A retrospective analysis was performed of early first-trimester (6-8 weeks' gestation) ultrasound images of women with AIP managed in the third trimester of pregnancy. We hypothesized that assessment of COS may identify cases of AIP at higher risk of intra- or postsurgical morbidity. Outcomes explored were estimated blood loss during surgery, need for and amount of packed red blood cells and fresh frozen plasma units required either during or after surgery, operative time, intrasurgical complications, gestational age at birth, delivery < 34 weeks of gestation, length of hospital stay and admission to intensive care unit. Differences in the explored outcomes were assessed among women with different types of COS variant (COS-1, COS-2+ or COS-2-) as observed on first-trimester ultrasound examination.
RESULTS: Sixty-eight pregnancies were included in the study. Mean estimated blood loss was higher in AIP pregnancies with COS-1 than in those with COS-2+ (P = 0.039) or COS-2- (P = 0.01). Mean number of packed red blood cell units required during or after the operation was higher in women with COS-1 compared with those with COS-2+ (P = 0.001) and COS-2- (P = 0.029), while there was no difference between pregnancies with COS-2+ and those with COS-2- (P = 0.797). Mean operative time was longer in AIP pregnancies with COS-1 than in those with COS-2+ (P = 0.039) or COS-2- (P = 0.017). Finally, pregnancies with COS-1 were delivered earlier than those with COS-2+ (P = 0.0001) or COS-2- (P = 0.0001).
CONCLUSION: First-trimester ultrasound assessment of the relationship between the ectopic gestational sac and the endometrial line (COS) may identify women with AIP who are at higher risk of intra- or postsurgical morbidity.
Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cesarean scar pregnancy; abnormal invasive placenta; increta; percreta; placenta accreta

Mesh:

Year:  2018        PMID: 28233462     DOI: 10.1002/uog.17440

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  4 in total

1.  Surgical outcomes of cesarean scar pregnancy: an 8-year experience at a single institution.

Authors:  Xiaofeng Xu; Dongdong Li; Lan Yang; Xiujuan Jing; Xiangyi Kong; Dezhu Chen; Tong Ru; Huaijun Zhou
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

2.  Placenta previa with posterior extrauterine adhesion: clinical features and management practice.

Authors:  Yoshikazu Nagase; Shinya Matsuzaki; Masayuki Endo; Takeya Hara; Aiko Okada; Kazuya Mimura; Kosuke Hiramatsu; Aiko Kakigano; Erika Nakatsuka; Tatsuya Miyake; Tsuyoshi Takiuchi; Yutaka Ueda; Takuji Tomimatsu; Tadashi Kimura
Journal:  BMC Surg       Date:  2021-01-06       Impact factor: 2.102

3.  Cesarean Scar Pregnancy Successfully Managed to Term: When the Patient Is Determined to Keep the Pregnancy.

Authors:  Ranko Kutlesic; Marija Kutlesic; Predrag Vukomanovic; Milan Stefanovic; Danka Mostic-Stanisic
Journal:  Medicina (Kaunas)       Date:  2020-09-24       Impact factor: 2.430

4.  Value of Crossover Sign in Anticipating Under-8-week Cesarean Scar Pregnancy Treatment by Foley Insertion Combined with Suction Curettage in Vietnam.

Authors:  Tuan Minh Vo; Hoang T Dinh; Thong P Van; Christopher Son Nguyen
Journal:  Gynecol Minim Invasive Ther       Date:  2021-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.